As of 2025-07-06, the EV/EBITDA ratio of Lineage Cell Therapeutics Inc (LCTX) is -10.66. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LCTX's latest enterprise value is 182.86 mil USD. LCTX's TTM EBITDA according to its financial statements is -17.15 mil USD. Dividing these 2 quantities gives us the above LCTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-07-03 | -10.66 |
| 2025-07-02 | -10.79 |
| 2025-07-01 | -9.17 |
| 2025-06-30 | -9.29 |
| 2025-06-27 | -9.66 |
| 2025-06-26 | -10.05 |
| 2025-06-25 | -11.46 |
| 2025-06-24 | -11.59 |
| 2025-06-23 | -9.99 |
| 2025-06-20 | -9.86 |
| 2025-06-18 | -9.40 |
| 2025-06-17 | -8.64 |
| 2025-06-16 | -8.73 |
| 2025-06-13 | -8.00 |
| 2025-06-12 | -6.57 |
| 2025-06-11 | -6.54 |
| 2025-06-10 | -7.13 |
| 2025-06-09 | -6.78 |
| 2025-06-06 | -6.20 |
| 2025-06-05 | -5.96 |
| 2025-06-04 | -5.98 |
| 2025-06-03 | -6.24 |
| 2025-06-02 | -6.07 |
| 2025-05-30 | -6.06 |
| 2025-05-29 | -6.35 |
| 2025-05-28 | -5.90 |
| 2025-05-27 | -6.31 |
| 2025-05-23 | -6.52 |
| 2025-05-22 | -5.26 |
| 2025-05-21 | -4.02 |
| 2025-05-20 | -3.68 |
| 2025-05-19 | -3.84 |
| 2025-05-16 | -3.38 |
| 2025-05-15 | -3.48 |
| 2025-05-14 | -3.31 |
| 2025-05-13 | -3.47 |
| 2025-05-12 | -3.59 |
| 2025-05-09 | -3.07 |
| 2025-05-08 | -3.47 |
| 2025-05-07 | -3.13 |
| 2025-05-06 | -3.01 |
| 2025-05-05 | -3.32 |
| 2025-05-02 | -3.75 |
| 2025-05-01 | -3.92 |
| 2025-04-30 | -3.86 |
| 2025-04-29 | -3.48 |
| 2025-04-28 | -3.34 |
| 2025-04-25 | -3.74 |
| 2025-04-24 | -3.85 |
| 2025-04-23 | -3.50 |